Dementia with Lewy bodies

Jan 27, 2020

Pacific Neuroscience Institute Offers Final Enrollment into Important Clinical Trial for Patients with Lewy Body Dementia

Nov 07, 2019

EIP Pharma Announces U.S. FDA Grants Fast-Track Designation to Neflamapimod as a Treatment for Dementia with Lewy Bodies (DLB)

Jul 15, 2019

Advances In The Global Search For Blood Markers For Alzheimer's Disease And Other Dementias

Jul 12, 2019

EIP Pharma Initiates New Study with Neflamapimod for the Treatment of Cognitive Deficits in Patients with Dementia with Lewy Bodies

Apr 15, 2019

EIP Pharma Closes $11.2 Million Financing Round to Advance Development of Neflamapimod in Additional Neurodegenerative Disease Indications

Sep 18, 2018

Sosei Provides Update on HTL0018318

Apr 06, 2018

FAU Named A 'Research Center Of Excellence' For Lewy Body Dementia

Sep 26, 2017

Axovant Announces Negative Topline Results of Intepirdine Phase 3 MINDSET Trial in Alzheimer's Disease

Aug 07, 2017

Axovant Announces Fiscal First Quarter Financial Results and Corporate Updates

Jun 19, 2017

FDA Grants Fast Track Designation to Axovant's Nelotanserin for Visual Hallucinations in Dementia with Lewy Bodies

Jun 13, 2017

Axovant Sciences Announces Fiscal Year-End Financial Results and Corporate Updates

Jun 08, 2017

New Criteria and Biomarker Tests Allow Physicians to Diagnose Dementia with Lewy Bodies in Early Stages